Complete response in Patients With Lung-Only Metastatic Prostate Cancer: Outcome Analysis

Adam M. Kase, John A. Copland, Qihui Zhai, Winston Tan

Research output: Contribution to journalArticlepeer-review


Lung-only metastatic prostate cancer can be seen in 4.6% of patients and historically patients with visceral metastastic disease are considered high risk. In order to determine survival outcomes in this patient population, we conducted a restrospective review of patients with metastatic hormone sensitive prostate cancer with lung-only metastases. In this single institution review, 10 patients were identified with 8 achieving a complete response and 2 achieving a partial response when treated with androgen deprevation therapy (ADT) with or without metastastetomy. The median progression free survival was 64.4 months with 8 of these patients (80%) with ongoing complete response at time of follow-up. Lung-only metastases may serve as a good prognostic characteristic which will allow the clinician to treat with ADT alone with or without surgery to minimize treatment realted toxicity and still offer the ability to achieve a complete response with prolonged survival.

Original languageEnglish (US)
Pages (from-to)e485-e489
JournalClinical Genitourinary Cancer
Issue number6
StatePublished - Dec 2022


  • Androgen deprivation therapy (ADT)
  • Complete response
  • Lung metastases
  • Lung-only metastatic prostate cancer
  • Metastatic hormone sensitive prostate cancer
  • Oligometastatic prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Complete response in Patients With Lung-Only Metastatic Prostate Cancer: Outcome Analysis'. Together they form a unique fingerprint.

Cite this